164 related articles for article (PubMed ID: 11401666)
21. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
Cohen PR; Rapin RP; Farhood AI
Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477
[No Abstract] [Full Text] [Related]
22. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
23. Nucleolar organizer regions in fibrohistiocytic tumors of the skin.
Merot Y; Durgniat AC; Frenk E
J Cutan Pathol; 1990 Apr; 17(2):122-6. PubMed ID: 1692574
[TBL] [Abstract][Full Text] [Related]
24. CD34+ pigmented fibrous proliferations: the morphologic overlap between pigmented dermatofibromas and Bednar tumors.
McAllister JC; Recht B; Hoffman TE; Sundram UN
Am J Dermatopathol; 2008 Oct; 30(5):484-7. PubMed ID: 18806495
[TBL] [Abstract][Full Text] [Related]
25. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
26. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
27. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
[TBL] [Abstract][Full Text] [Related]
28. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
29. Melanoma associated with a dermatofibroma.
Kovach BT; Boyd AS
J Cutan Pathol; 2007 May; 34(5):420-2. PubMed ID: 17448199
[TBL] [Abstract][Full Text] [Related]
30. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
32. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles.
Hsi ED; Nickoloff BJ
J Dermatol Sci; 1996 Jan; 11(1):1-9. PubMed ID: 8867761
[TBL] [Abstract][Full Text] [Related]
33. Microphthalmia-associated transcription factor (MiTF): Promiscuous staining patterns in fibrohistiocytic lesions is a potential pitfall.
Mohanty SK; Sharma S; Pradhan D; Kandukuri SR; Farahani N; Barry C; Wu JM; Frishberg D; Balzer B
Pathol Res Pract; 2018 Jun; 214(6):821-825. PubMed ID: 29773427
[TBL] [Abstract][Full Text] [Related]
34. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Nikaido O; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Jun; 14(6):581-8. PubMed ID: 11406660
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
36. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
Labonte S; Hanna W; Bandarchi-Chamkhaleh B
J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
[TBL] [Abstract][Full Text] [Related]
37. [Fibrohistiocytic tumor of skin].
Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):134-7. PubMed ID: 23710926
[No Abstract] [Full Text] [Related]
38. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
39. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
Okita H; Ohtsuka T; Yamazaki S
Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
[TBL] [Abstract][Full Text] [Related]
40. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.
Hartel PH; Jackson J; Ducatman BS; Zhang P
J Cutan Pathol; 2006 Sep; 33 Suppl 2():24-8. PubMed ID: 16972949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
